Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is effective and safe in the treatment of hyperlipidemia in chronic kidney disease stage 3 - 4
{{output}}
Aims: To evaluate the efficacy and safety of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in chronic kidney disease (CKD). Backg... ...
